CME/CE - PACE-CME

Episodes 81-96 of 100

MinuteCE®
New paradigms in the prevention of ASCVD: The role of EPA and triglycerides
1.00 credit 3 episodes
- Richard Hobbs, MD
- Lale Tokgözoğlu, MD
- Victor Aboyans, MD, PhD
1.00 credit 3 episodes
The benefits of icosapent ethyl in addressing residual risk: What is the evidence?
The benefits of icosapent ethyl in addressing residual risk: What is the evidence?
MinuteCE®
The benefits of icosapent ethyl in addressing residual risk: What is the evidence?
1.00 program credit
- Lale Tokgözoğlu, MD
1.00 program credit
Reassessing the role of triglycerides in residual cardiovascular risk
Reassessing the role of triglycerides in residual cardiovascular risk
MinuteCE®
Reassessing the role of triglycerides in residual cardiovascular risk
1.00 program credit
- Richard Hobbs, MD
1.00 program credit
Practical experience and model for optimizing RAASi-based therapy in HF
Practical experience and model for optimizing RAASi-based therapy in HF
MinuteCE®
Practical experience and model for optimizing RAASi-based therapy in HF
1.00 program credit
- Aaron Wong, MD
1.00 program credit
MinuteCE®
Breaking barriers in guideline-based RAASi therapy: Solving issues with hyperkalemia
1.00 credit 3 episodes
- Shelley Zieroth, MD
- Mikhail Kosiborod, MD
- Aaron Wong, MD
1.00 credit 3 episodes
Continuing foundational therapy in symptomatic HF: the key role of RAASi-based therapy
Continuing foundational therapy in symptomatic HF: the key role of RAASi-based therapy
MinuteCE®
Continuing foundational therapy in symptomatic HF: the key role of RAASi-based therapy
1.00 program credit
- Shelley Zieroth, MD
1.00 program credit
What to do if potassium levels increase in HF?
What to do if potassium levels increase in HF?
MinuteCE®
What to do if potassium levels increase in HF?
1.00 program credit
- Mikhail Kosiborod, MD
1.00 program credit
MinuteCE®
Hypertrophic cardiomyopathy & heart failure: exploring new options
1.00 credit 3 episodes
- Rudolf de Boer, MD, PhD
- Mariana Brandão, MD
- Iacopo Olivotto, MD
1.00 credit 3 episodes
Managing patients with HCM and HF: what’s new in the therapeutic landscape?
Managing patients with HCM and HF: what’s new in the therapeutic landscape?
MinuteCE®
Managing patients with HCM and HF: what’s new in the therapeutic landscape?
1.00 program credit
- Iacopo Olivotto, MD
1.00 program credit
HCM and heart failure: is your patient at risk?
HCM and heart failure: is your patient at risk?
MinuteCE®
HCM and heart failure: is your patient at risk?
1.00 program credit
- Rudolf de Boer, MD, PhD
1.00 program credit
Recognizing HCM and HF: making the diagnosis
Recognizing HCM and HF: making the diagnosis
MinuteCE®
Recognizing HCM and HF: making the diagnosis
1.00 program credit
- Mariana Brandão, MD
1.00 program credit
What is the evidence of SGLT2i in CKD?
What is the evidence of SGLT2i in CKD?
MinuteCE®
What is the evidence of SGLT2i in CKD?
1.00 program credit
- Hiddo L. Heerspink, PhD
1.00 program credit
When and how to initiate SGLT2i in CKD
When and how to initiate SGLT2i in CKD
MinuteCE®
When and how to initiate SGLT2i in CKD
1.00 program credit
- David Wheeler, MB, CHB, MD, FRCP
1.00 program credit
Primary care role in CKD
Primary care role in CKD
MinuteCE®
Primary care role in CKD
1.00 program credit
- Richard Hobbs, MD
1.00 program credit
A call to action: optimizing treatment in CKD
A call to action: optimizing treatment in CKD
MinuteCE®
A call to action: optimizing treatment in CKD
1.00 program credit
- Meg Jardine, MD, PhD
1.00 program credit
MinuteCE®
4 things to know about CKD and SGLT2i
1.00 credit 4 episodes
- Hiddo L. Heerspink, PhD
- David Wheeler, MB, CHB, MD, FRCP
- Meg Jardine, MD, PhD
- Richard Hobbs, MD
1.00 credit 4 episodes

6/7